Ronald L Krall

Learn More
Thirty-two patients with spasticity due to multiple sclerosis were entered into a randomized, double-blinded, placebo-controlled crossover trial of the gamma-aminobutyric acid agonist, progabide. Each patient was treated with a maximum of 45 mg/kg of progabide during each of two four-week treatment periods, separated by a two-week washout. Twenty-five(More)
A critical challenge facing the advocates of biotechnology is to fortify the biosafety of genetically engineered organisms. Readers of this journal have seen competing notions on how to achieve biosafety. For some, scientists carry the burden of designing better biosafety through 'backup safety precau-tions' 1 and 'molecular gene-containment strategies' 2.(More)
  • 1